SCHEMBL577953

SCHEMBL577953

O=c1nc(Cl)[nH]c2ccccc12

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.52
RAB9A P51151 1/20 0.52
KDM4E B2RXH2 8/20 0.50
ALDH1A1 P00352 7/20 0.50
LMNA P02545 2/20 0.50
HPGD P15428 2/20 0.50
GAA P10253 2/20 0.50
GLA P06280 1/20 0.50
HTT P42858 1/20 0.50
ATM Q13315 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
PARP1 P09874 5/20 0.47
HSD17B10 Q99714 3/20 0.47
CYP1A2 P05177 3/20 0.47
GPR3 P46089 2/20 0.47
TNKS2 Q9H2K2 2/20 0.47
KMT2A Q03164 2/20 0.47
MEN1 O00255 1/20 0.47
TNKS O95271 1/20 0.47
BLM P54132 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30014118 1.00 NPC1 (0.52) NPC1RAB9AKDM4EALDH1A1LMNA
SCHEMBL6887071 0.81 ALDH1A1 (0.52) NPC1RAB9AKDM4EALDH1A1LMNA
SCHEMBL103993 0.78 ALDH1A1 (0.53) KDM4EALDH1A1LMNAHPGDGAA
SCHEMBL1590490 0.78 ALDH1A1 (0.61) NPC1KDM4EALDH1A1LMNAHPGD
SCHEMBL3253183 0.78 ALDH1A1 (0.48) KDM4EALDH1A1LMNAHPGDGAA
Benzoylenurea SCHEMBL4559940 0.78 ALDH1A1 (0.50) KDM4EALDH1A1LMNAHPGDGAA
SCHEMBL2767091 0.77 ALDH1A1 (0.47) NPC1RAB9AKDM4EALDH1A1LMNA
SCHEMBL9769434 0.77 MEN1 (0.49) KDM4EALDH1A1LMNAHPGDGAA
SCHEMBL8623118 0.77 PTGES (0.63) NPC1RAB9AKDM4EALDH1A1GAA
SCHEMBL8618923 0.77 TNKS (0.59) NPC1RAB9AKDM4EALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250361236-A9 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS GILEAD SCIENCES INC (US) 2025-11-27 US disclosed
EP-4631933-A1 NOVEL 2-((TRANS-4-(4-ARYLOXY)CYCLOHEXYL)AMINO)QUINAZOLINONE DERIVATIVE AND METHOD FOR PREPARING SAME NexThera Co., Ltd. (KR) 2025-10-15 EP disclosed
US-20240400568-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS GILEAD SCIENCES, INC. 2024-12-05 US disclosed
EP-4445902-A2 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS Carna Biosciences, Inc. (JP) 2024-10-16 EP disclosed
EP-4081305-B1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS CARNA BIOSCIENCES INC (JP) 2024-09-18 EP disclosed
US-12054490-B2 Diacylglycerol kinase modulating compounds GILEAD SCIENCES, INC. (US) 2024-08-06 US disclosed
CN-118324767-A Diacylglycerol kinase modulating compounds 卡尔那生物科学株式会社 2024-07-12 CN disclosed
WO-2024122961-A1 NOVEL 2-((TRANS-4-(4-ARYLOXY)CYCLOHEXYL)AMINO)QUINAZOLINONE DERIVATIVE AND METHOD FOR PREPARING SAME 부산대학교 산학협력단 2024-06-13 WO disclosed
WO-2024123038-A1 NOVEL 2-((TRANS-4-(4-ARYLOXY)CYCLOHEXYL)AMINO)QUINAZOLINONE DERIVATIVE AND METHOD FOR PREPARING SAME 주식회사 넥스세라 2024-06-13 WO disclosed
US-20240182476-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS GILEAD SCIENCES, INC. 2024-06-06 US disclosed
EP-0946095-A1 FUNGICIDAL QUINAZOLINONES E.I. DU PONT DE NEMOURS AND COMPANY (US) 1999-10-06 EP disclosed
WO-1998026664-A1 FUNGICIDAL QUINAZOLINONES E.I. DU PONT DE NEMOURS AND COMPANY (US) 1998-06-25 WO disclosed
EP-0411766-B1 Substituted quinazolinones as angiotensin II antagonists MERCK & CO INC (US) 1994-01-19 EP disclosed
EP-0517357-A1 Angiotensin II antagonists incorporating a substituted indole or dihydroindole MERCK & CO. INC. (US) 1992-12-09 EP disclosed
EP-0515535-A1 ANGIOTENSIN II ANTAGONISTS INCORPORATING A SUBSTITUTED BENZYL ELEMENT MERCK & CO. INC. (US) 1992-12-02 EP disclosed
EP-0512870-A1 Substituted quinazolinones bearing acidic functional groups as angiotensin II antagonists MERCK & CO. INC. (US) 1992-11-11 EP disclosed
EP-0512676-A1 Angiotensin II antagonists incorporating a substituted benzyl element MERCK & CO. INC. (US) 1992-11-11 EP disclosed
EP-0510812-A1 Angiotensin II antagonists incorporating a substituted thiophene or furan MERCK & CO. INC. (US) 1992-10-28 EP disclosed
WO-1991012001-A1 ANGIOTENSIN II ANTAGONISTS INCORPORATING A SUBSTITUTED BENZYL ELEMENT MERCK & CO., INC. (US) 1991-08-22 WO disclosed
EP-0411766-A1 Substituted quinazolinones as angiotensin II antagonists MERCK & CO. INC. (US) 1991-02-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240400568-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS DGKG, DGKB, DGKK NPC1 991/4885RAB9A 1568/4885KDM4E 1748/4885
US-12054490-B2 Diacylglycerol kinase modulating compounds DGKG, DGKB, DGKK NPC1 991/4885RAB9A 1568/4885KDM4E 1748/4885
US-20240182476-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS DGKG, DGKB, DGKK NPC1 991/4885RAB9A 1568/4885KDM4E 1748/4885
US-20250361236-A9 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS DGKG, DGKB, DGKK NPC1 991/4885RAB9A 1568/4885KDM4E 1748/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.